Author: Editor

Soeren Mattke, MD DSc, University of Southern California, Los Angeles, USA
Mo Wang, MS, University of Southern California, Los Angeles, USA

The emerging disease-modifying Alzheimer’s treatments present a health system challenge because of the combination of a large prevalent patient pool and a complex diagnostic process. Analyses of system preparedness have projected Canada to have the longest and most protracted wait times for access among G7 countries. This policy analysis used comparative health system data and 17 semi-structured interviews with experts in Canada. The authors conclude that Canada faces a unique challenge to make a disease-modifying Alzheimer’s treatment accessible because of limited capacity for memory care.

PREVIEW: January 27, 2022 | PUBLISHED: January 31, 2022

Mayvis Rebeira, PhD, Affiliated Scholar, Canadian Health Policy Institute

This commentary article compares Canada’s vaccination procurement strategy with that of UK and Israel. Canada’s COVID-19 vaccine supply seemed unreliable in the early months of 2021 when both UK and Israel were able to procure a steady supply of vaccines for their population. As of the beginning of May 2021, Canada had only fully vaccinated (two doses administered) 3% of its population compared to Israel at 58% and UK at 23%. Canada eventually accelerated its vaccine distribution and by the end of August 2021, 66% of the population had been fully vaccinated.

PUBLISHED: September 23, 2021